First patient receives BHB810 in BigHat Biosciences’ Phase I study

BigHat Biosciences has dosed the patient in a Phase I clinical trial of BHB810 to treat gastric cancer and other advanced GI malignancies. The trial will administer BHB810 to patients with advanced gastric and gastroesophageal tumours. BHB810 was developed as a VHH-Fc antibody-drug conjugate. Credit: Gorodenkoff / Shutterstock.com. BigHat Biosciences has dosed the patient in a Phase I clinical trial of BHB810, an antibody-drug conjugate targeting Cadherin-17 (CDH17), for the treatment of gastric cancer and other advanced gastrointestinal (GI) malignancies. The trial will initially administer BHB810, designed using BigHat Biosciences’ AI platform, to patients with advanced gastric and gastroesophageal tumours.…

Source: Clinical Trials Arena